Bothering To Look: With New Tools, Biotech Goes Back To The Black Box
This article was originally published in Start Up
For decades drug discovery meant testing new compounds in cells and animals without knowing how or why they might work. A shift to reductionist, target-based discovery has done little to nothing to bring more drugs to market. Proponents say it’s time for more phenotypic inquiry early in the drug discovery process, bolstered when possible by better tools and technology.